Italy: IP And The Pharmaceutical Industry In Italy (Patents And Supplementary Protection)

Last Updated: 5 November 1997
Until recently the pharmaceutical Industry had been complaining of the inadequacy of the Intellectual Property protection available in Italy, and, as far as national industry was concerned, of the negative effect that this was having on its competitiveness with foreign manufacturers, which were granted with a broader protection in their jurisdictions.

It may be useful, in order to understand the present situation and to make a long story short, to briefly summarise the developments occured in the subject matter.

First, it is worth noting that it was not until 1978 that patent protection became available to pharmaceutical products in Italy, when the Constitutional Court pronounced, with its judgment of 20th March 1978, no. 20, the unconstitutionality of art. 14 of r.d. 29th June 1939, no. 1127 (the law on industrial inventions) which prohibited the granting of patents to pharmaceutical inventions, on the ground of some dubious "moral" justifications.

However, despite this important amendment to the law, the pharmaceutical industry found that such reform was inadequate and insufficient. As a matter of fact, while normal patent protection runs for twenty years from the date when the request for patent protection is filed, its manufacturer is immediately able to exploit his product commercially; not so for the producers of pharmaceutical products, who must first obtain authorisation to market their products from the health authorities by means of registration by the Ministry for the Interior in accordance with art. 162 of the unified text of the health laws, no. 1265/1934 as amended by art. 4 of the law no. 422/1941.

Unfortunately, the scientific and technical effort involved in obtaining such authorisation, which is often out of all proportion to the importance of the innovation, leads to long delays before commercialisation is possible. Typically, this leads to delays of up to twelve years from the date of filing the request for patent protection until authorisation is granted so that the actual period which remains for commercial exploitation of the patented product is reduced to eight years.

Thus, with the entering into force of the law of 19th October 1991, no. 349, and the advent of the Supplementary Protection Certificate, a new system of supplementary patent protection was introduced for pharmaceutical products and compounds which are capable of being the object of protection.

It is hardly necessary to say that the idea of the Supplemental Protection Certificate was not an Italian innovation, but one inspired by other legal systems such as those of France, the United States and Japan. The United States and Japan both chose to deal with the problem by introducing the extension of the original period of patent protection.

This approach, however, was not open to Italy or to the other signatories of the Munich and Luxembourg Conventions relating to European and Community patents which established that the twenty year duration of the patent could not be varied by national legislation. It is worth noting here that the European Community also deemed it necessary to introduce Supplementary Protection Certificates for European Patents relating to pharmaceuticals with its Regulation no. 1768/92.

The system of Supplementary Protection Certificates is, however, compatible with the Munich Convention on the European Patent since the Convention does not prevent the signatories from extending patent protection by introducing additional means of protection.

Given the importance of the patent as a method for protecting and nurturing scientific innovation, it is not surprising that the Supplementary Protection Certificates have the same effect (and the same limitations) as the original "base" patent grant.

In Italy, it is possible to request a Supplementary Protection Certificate for Italian patents or for patents having effect in Italy and which relate to pharmaceuticals, use of products as medication and processes for their manufacture.

Turning to the provisions of the Law of no. 349/91, the most significant of the transitional measures are found in article 4 and in accordance with which:

  • requests for grants of patent filed before 18th May 1972 are excluded;
  • owners of pharmaceutical patents who obtained the first ministerial authorisation to market the product before 19th November 1991 and who filed the request for the patent between 18th May 1972 and 13th November 1972 can request a Certificate up to 180 days before the expiry of the patent.
Otherwise, a Certificate may be requested by the owner of the patent within 180 days of the grant of the first ministerial authorisation and, in any event, at least 180 days before the expiry of the patent. In the event that the first authorisation is given before the grant of the patent, a Certificate can be requested within six months of the date of the grant of the patent.

The effect of the Certificate is to extend the duration of the protection for a period equal to the length of time which passes between the date of filing the request for the patent and the date of first authorisation but, in any case, for a maximum period of 18 years.

A Certificate will only be granted on the basis of one patent. In the event that a product is protected by more than one patent, for example, one for the product itself and one for the production process, it is up to the owner of such patents to choose which is to be the "base" patent on which the application for a Certificate will be made. This is particularly important as the protection afforded by the Certificate will be limited to that given by the original patent.

It should also be noted that one product often receives a number of successive authorisations for its commercialisation when, for example, a change is made to its form, to the dosage, to its composition etc. In this case it is the first authorisation that is relevant for the purposes of calculating the time that has passed since the request for the patent was made.

It goes without saying that the "base" patent should be valid and current, as should the authorisation, failing which the Certificate will be void. Care should be taken, since, in the pharmaceutical field, one patent may protect a number of products which conform to the same formula. Of those products, only some will be developed and, eventually, only one will be put on the market. In this case, the Certificate will only protect the product covered by the ministerial authorisation and not the rest of the products covered by the one patent.

In the same way, the protection given by a Certificate to a product which has been authorised will be limited to the subject matter of the "base" patent. Therefore, if an authorised product is made up of more than one active compound, only the compound that is protected by the patent will be protected by the Certificate.

In the event that a party wishes to challenge the validity of the Supplementary Protection Certificate, a request to have a Certificate declared void may be made to the body which first granted it, i.e. to l'Ufficio Italiano Brevetti e Marchi. A Certificate may be declared void for one of the three following reasons:

  • if the conditions for obtaining the Certificate in accordance with art. 4bis of the Law are not fulfilled and, in particular, if the ministerial authorisation is void or was not the first to have been made with respect to that product, or if the "base" patent was no longer valid at the time of requesting a Certificate; or
  • if the "base" patent is void at the date of its legal expiry, or is subsequently declared void. Thus, it is possible to obtain the annulment of the "base" patent after the date for its legal expiry but only in order to obtain annulment of the Certificate; or
  • If the product which is protected by the Certificate is not protected by the "base" patent.
In conclusion, the purpose of the Law no. 349/91 is to extend the length of patent protection actually available to pharmaceutical products, not so that such products enjoy a privileged position, but so that they may enjoy the same length of protection as non-pharmaceutical products and, thus, put an end to the penalising effect that this has had on the Italian pharmaceutical industry with regard to its foreign competitors.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Mondaq Advice Centre (MACs)
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.